Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abiomed

Every Impella Heart Pump Controller Is Slated for Removal After Three Deaths, and Hospitals Will Keep Using Them

FDA flagged all Automated Impella Controllers for removal after 37 injuries and three deaths. Hospitals can keep using stock while awaiting service.

FDA Assigns Its Most Serious Recall Class to Heart Pump Introducers Weeks After Issuing an Early Alert

FDA Assigns Its Most Serious Recall Class to Heart Pump Introducers Weeks After Issuing an Early Alert

fda-class-i-recall-abiomed-oscor-impella-introducer-kits-2026

How High Can This Healthcare Stock Soar With Nvidia's Help?

How High Can This Healthcare Stock Soar With Nvidia's Help?

Dividend King J&J can boost its MedTech business with Nvidia’s help.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

He invented a successful medical device as a student. Here's his advice for new grads

When Thorsten Siess was in graduate school, he came up with the idea for a heart device that's now been used in hundreds of thousands of patients around the world.

The Strongest Pharma Stock This Week

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

1 Stock to Buy for Safety in This Volatile Market

With the Fed anticipating higher interest rate hikes than previously expected, the stock market is expected to remain volatile in the upcoming months. Given its strong balance sheet, brand recognition, and solid dividend payouts, it could be safe to invest in Johnson & Johnson (JNJ). Read more….

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Recap: Abiomed Q4 Earnings

Recap: Abiomed Q4 Earnings

Abiomed (NASDAQ:ABMD) reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

A Preview Of Abiomed's Earnings

A Preview Of Abiomed's Earnings

Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Abiomed will report an earnings per share (EPS) of $1.09.

What 4 Analyst Ratings Have To Say About Abiomed

What 4 Analyst Ratings Have To Say About Abiomed

Abiomed (NASDAQ:ABMD) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Abiomed's Return On Capital Employed Insights

Abiomed's Return On Capital Employed Insights

According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million.

Recap: Abiomed Q3 Earnings

Recap: Abiomed Q3 Earnings

Abiomed (NASDAQ:ABMD) reported its Q3 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Ominous Death Cross Forms On Abiomed's Chart

If history is any guide, there may be trouble ahead for shares of Abiomed (NASDAQ:ABMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Johnson & Johnson (

Palo Alto Networks

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

416,724 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play